Projects

Akromegalie ist ein sehr seltene Erkrankungen, deren Behandlung in vielerlei Hinsicht noch nicht ausreichend erforscht ist. Eine effektive Erforschung dieser Erkrankung setzt voraus, dass möglichst umfangreiche Informationen über möglichst viele Pati...

Clinical Studies - Sep 6, 2019 - Dec 31, 2029

Ongoing

Project leader: Krull Ina
Members: Bilz Stefan, Räss Andrea

A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy Randomisation 2:1:1:1 Cabo...

Clinical Studies - Sep 1, 2019 - Nov 28, 2020

Completed

Project leader: Semela David
Members: Stillhard Roman

Fundamental Research - Sep 1, 2019 - Mar 31, 2025

Ongoing

Project leader: Ludewig Burkhard
Members: Stanossek Yves, Meili Samuel, De Martin Angelina, Lütge Mechthild, Kurz Lisa, Cheng Hung-Wei

A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome

Clinical Studies - Aug 7, 2019 - Aug 30, 2020

Aborted

Project leader: Rickli Hans
Members: Vetsch Susanne

Untersuchung wie gut Menschen mit ALS, Emotionen in Gesichtsausdrücken erkennen können. Falls Resultate des Projekts ergeben sollte, dass ALS-Patienten in der Erkennung von Emotionen eingeschränkt sind, soll der im Rahmen des Projekts durchgeführte T...

Clinical Studies - Aug 1, 2019 - Dec 31, 2024

Ongoing

Project leader: Braun Nathalie

A PHASE 4, MULTICENTER, SINGLE-ARM, OPENLABEL STUDY TO EVALUATE THE IMPACT OF APREMILAST (CC-10004) ON MRI OUTCOMES IN SUBJECTS WITH PSORIATIC ARTHRITIS

Clinical Studies - Jul 31, 2019 - Aug 31, 2021

Completed

Project leader: Rubbert-Roth Andrea
Members: Bartz-Batliner Mira, Neumann Thomas, Sasselli Clelia, Peischl Riana

Main objective: To investigate efficacy of a stage-adapted tratment regimen in stage IIA/B seminoma based on the preliminary experience gained in SAKK 01/10. The Goal is to further safely de-escalate Treatment while maintaining / enhancing efficacy.

Clinical Studies - Jul 24, 2019 - Jul 24, 2030

Ongoing

Project leader: Putora Paul Martin
Members: Plasswilm Ludwig, Rothermundt Christian, Patzl Sigrid, Fischer Stefanie

MATAO- MAintenance Therapie mit Aromatasehemmer (Letrozol) für Patientinnen mit epithelialem Ovarialkarzinom: Eine randomisierte doppel-blinde Placebo-kontrollierte Phase III Studie inklusive LOGOS (LOw Grade Ovarian cancer Sub-study) (ENGOT-ov54/S...

Clinical Studies - Jul 18, 2019 - Dec 31, 2025

Ongoing

Project leader: Hornung René
Members: Baldinger Jeannette, Kozlova Aleksandra

A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with polymyalgia rheumatica

Clinical Studies - Jul 4, 2019 - Jul 8, 2021

Automatically Closed

Project leader: Rubbert-Roth Andrea
Members: Neumann Thomas, Bartz-Batliner Mira, Peischl Riana, Sasselli Clelia

A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis

Clinical Studies - Jul 4, 2019 - Jul 8, 2020

Aborted

Project leader: Rubbert-Roth Andrea
Members: Neumann Thomas, Bartz-Batliner Mira, Peischl Riana, Sasselli Clelia

Primary Objective: Randomised arm: To compare Long-term pain Response after dose- intensified imageguide hypofractioned SBRT employing SIB versus conventional Radiation therapy for painful spinal metastasis Prospective observational arm: To assess t...

Clinical Studies - Jul 3, 2019 - Jul 3, 2024

Automatically Closed

Project leader: Henke Guido
Members: Panje Cédric, Glatzer Markus

Background: In patients suffering from aneurysmal subarachnoid hemorrhage (aSAH) devastating and largely unpredictable sequels such as re-bleeding, cerebral vasospasm and delayed cerebral ischemia have a large impact on patient outcome. However, unti...

Clinical Studies - Jul 1, 2019 - Jul 1, 2020

Automatically Closed

Project leader: Maldaner Nicolai

Breast cancer is the most frequent malignancy in women and the leading cause of cancer mortality in most countries in Europe. Metastatic breast cancer remains an incurable disease with a median overall survival (OS) of 2–4 years and a 5 year surviv...

Clinical Studies - Jun 25, 2019 - Dec 31, 2026

Ongoing

Project leader: Hasler-Strub Ursula

Evaluation einer Immuntherapie in der ersten Therapielinie in Kombination mit einer Standard Chemo-/Avastintherapie bei Patienten mit malignem Mesotheliom

Clinical Studies - Jun 20, 2019 - Jul 4, 2025

Ongoing

Project leader: Früh Martin

In this study, a collaborative work with EMBL Heidelberg, ETH- D BSSE Empa (Materials Science and Technology), we deciphered –hitherto unknown- resistance mechanisms of P. aeruginosa to ceftazidime- avibactam (CZA), a novel antibiotic with a multi-o...

Fundamental Research - Jun 20, 2019 - Jan 1, 2023

Automatically Closed

Project leader: Babouee Flury Baharak, Kogadeeva-Zimmermann Maria

After tumor removal, patients with hormone receptor posi-tive breast cancer often receive adjuvant endocrine treat-ment, with the use of an aromatase inhibitor (AI) being standard of care in the population of postmenopausal women. Common side effects...

Fundamental Research - Jun 17, 2019 - Aug 2, 2024

Automatically Closed

Targeted therapy beyond Progression with or without dose-intensified radiotHerapy in oligo-progressive disease (OPD) in oncogene Addicted Lung Tumors (HALT) Objectives: To determine wether in patients with Mutation positive advanced NSCLC the use of...

Clinical Studies - Jun 12, 2019 - Feb 1, 2021

Automatically Closed

Project leader: Glatzer Markus

Primary central nervous system lymphomas (PCNSL) are rare aggressive malignancies, mostly of B-cell origin, representing 4% of intracranial neoplasms and 4-6% of extranodal non-Hodgkin's lymphomas (NHL). Despite improvements in treat-ment, PCNSL is a...

Clinical Studies - Jun 7, 2019 - Jun 27, 2024

Automatically Closed

To compare metastases-free survival (MFS) between metastasis-directed therapy and metastases-directed therapy with whole pelvis radiotherapy for oligorecurrent nodal prostate cancer. Target: 178 Patients

Clinical Studies - Jun 1, 2019 - Jul 1, 2025

Ongoing

Project leader: Putora Paul Martin

Geschmacksstörungen (Dysgeusie) während einer Chemotherapie aufgrund einer Krebserkrankung sind häufig und beeinträchtigen die Lebensqualität erheblich. Bisher gibt es keine wirksamen Behandlungsmassnahmen. In einer randomisierten, kontrollierten, ve...

Clinical Studies - Jun 1, 2019 - Dec 31, 2024

Ongoing

Project leader: Schlaeppi Marc